Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
April 24, 2023 16:01 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development
April 06, 2022 08:00 ET
|
Morphic Therapeutic
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron Pelta promoted to Senior Vice President, Business and Corporate Development;...